# Exo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exo-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.exo-therapeutics.com
- Total disclosed funding: $103M
- Latest round: Series B (Oct 3, 2021)
- Investors on record: 9

## About

Exo Therapeutics, Inc. is focused on creating innovative therapies aimed at difficult drug targets, utilizing its proprietary ExoSight™ platform to develop exosite inhibitors for treating various inflammatory conditions and cancers.Founded in 2018 and headquartered in Cambridge, US, Exo Therapeutics, Inc. develops transformative therapies targeting intractable drug targets. The company raised USD 77.82 mn in Series B funding on October 3, 2021, led by Nextech, with other contributors including BVF Partners and Novartis Venture Fund. The founder, Juan Maianti, has a history of entrepreneurship in the biotech sector, although prior ventures are not specified.Exo Therapeutics, Inc. specializes in innovative therapies targeting intractable drug targets through its proprietary ExoSight™ platform. The company’s core product offerings include exosite inhibitors, particularly the EXO-TBKi, which disrupts STING-mediated TBK1 activation linked to inflammatory conditions and oncology applications. These inhibitors are intended for the treatment of autoimmune diseases and cancers, serving a client base of pharmaceutical companies, research institutions, and healthcare providers across North America and Europe.Exo Therapeutics generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research organizations. Their business model primarily revolves around B2B agreements, which may include licensing agreements or co-development deals for utilizing Exo Therapeutics' exosite inhibitors. Although specific pricing plans are not disclosed, financial arrangements typically involve milestone payments and royalties tied to the success of therapies in the pharmaceutical market, with the EXO-TBKi being a key component of their revenue strategy.Exo Therapeutics, Inc. plans to leverage its recent Series B funding of USD 77.82 mn to further develop treatment concepts in cancer and inflammation using its ExoSight™ technology, advancing them to proof-of-concept and clinical trials. The company aims to explore additional targets with the ExoSight platform. Future expansion efforts include entering new markets in Asia and Europe by 2023, enhancing their geographical footprint and addressing unmet medical needs.

## Funding rounds

- Series B, Oct 3, 2021, $78M — CRV, Novartis Venture Fund, 5Y Capital, Nextech, Casdin Capital, BVF Partners, 6 Dimensions Capital, Samsara BioCapital, Newpath Partners
- Series A, Dec 16, 2020, $25M — CRV, Novartis Venture Fund, 6 Dimensions Capital, Newpath Partners

## Investors

- CRV (https://capitalatlas.ai/funds/crv) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A, Series B
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series A, Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B